secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021203
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences Q1 2023 net loss $22.2M; cash $257.7M; trials on track
--------------------------------------------------------------------------

- Net loss of $22.2M ($0.31 per share) vs $16.0M ($0.26 per share) in Q1 2022.
- Cash, cash equivalents and marketable securities $257.7M as of March 31, 2023, down from $276.6M at Dec 31, 2022.
- R&D expenses increased to $18.3M from $10.9M, driven by advancing zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b trial of zetomipzomib in lupus nephritis on track to initiate in H1 2023.
- KZR-261 dose escalation study enrolling Cohort 6; dose expansion expected H2 2023 with topline data mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/0000950170-23-021203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023021203/kzr-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer